Mag3 Radiopharmacy

Betiatide, the active ingredient in Mag3 Radiopharmacy, is a radiopharmaceutical presented as a sterile solution for intravenous use. It is employed in diagnostic imaging to evaluate renal perfusion and excretory function.

GNH USA supplies Mag3 Radiopharmacy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Betiatide is used in diagnostic imaging of the renal system.

Renal imaging: enables visualization of kidney perfusion and excretion to assess function and drainage. Renal transplant evaluation: assists in monitoring graft perfusion and function post‑transplant. Urography: supports assessment of urinary tract obstruction.

Adverse reactions may occur following administration of Betiatide.

Common Side Effects: - Nausea: mild to moderate feeling of sickness. - Vomiting: occasional emesis after injection. - Headache: transient mild headache. - Transient flushing: brief skin redness. - Metallic taste: brief sensation in mouth. - Mild hypotension: temporary drop in blood pressure.

Serious or Rare Side Effects: - Allergic reaction: rash, itching, or swelling. - Anaphylaxis: severe, potentially life‑threatening hypersensitivity. - Severe hypotension: marked blood pressure fall requiring intervention. - Radiation‑induced skin injury: localized skin changes at injection site. - Renal toxicity: worsening of kidney function. - Severe arrhythmia: abnormal heart rhythm requiring monitoring.

When using Betiatide, clinicians should observe several safety measures.

Assess renal function: evaluate baseline kidney function before administration. Pregnancy: avoid use unless the benefit clearly outweighs potential fetal risk. Breastfeeding: discontinue if possible, as the drug may be excreted in milk. Concurrent radiopharmaceuticals: avoid co‑administration to prevent imaging interference. Allergy history: screen for hypersensitivity to any component of the formulation. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Betiatide may interact with other medicines and agents.

Major Interactions (Avoid): - Nephrotoxic drugs: may exacerbate renal toxicity. - Competing radiopharmaceuticals: can interfere with imaging results. - Contrast agents: may alter renal clearance of Betiatide. - High‑dose diuretics: affect excretion pattern and image quality. - Radiation therapy: additive radiation exposure risk.

Moderate Interactions (Monitor Closely): - ACE inhibitors: may modify renal handling of the tracer. - NSAIDs: can affect renal perfusion and tracer distribution. - Beta‑blockers: may influence hemodynamics during imaging. - Antihistamines: could mask early signs of allergic reaction. - Electrolyte disturbances: monitor serum potassium and sodium levels.